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Abstract 
Review on TAL1 deletion in lymphoid malignancies 
with data on clinics. 
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Identity 
Note 
The deletion of the TAL 1 gene may be due to the 
deletion of the band 1p32 (del(1)(p32)) or to a 
submicroscopic interstitial deletion between the 
TAL1 and STIL genes (Note: STIL is better known 
as "SIL").  
The pathogenesis of the two deletions is different. 
The 1p32 deletion is probably related to the 
inactivation of a tumor suppressor gene or genes 
localized in the band 1p32, while the SIL-TAL1 
deletion to deregulation of the TAL1 gene. 
Del(1)(p32) is found in a variety of B or T lymphoid 
malignances and the SIL-TAL1 deletion is 
associated only with T-acute lymphoblastic 
leukemia (ALL).  
Until now 39 cases with del(1)(p32) have been 
reported: 9 cases with acute lymphoblastic 
leukemia/lymphoblastic lymphoma, 2 cases with 
adult T-cell lymphoma/ leukemia (HTLV-1+), 8 
cases with follicular lymphoma, 6 cases with diffuse 
large B-cell lymphoma, 3 cases with anaplastic large 
cell lymphoma, 2 cases with Hodgkin disease, 7 
cases with multiple myeloma and 2 cases with 
plasma cell leukemia.  
The 1p32 deletion can be detected by conventional 
cytogenetics, and the SIL-TAL1 deletion by 
fluorescence in situ hybridization, Southern blot 
analysis and real time PCR. 
Clinics and pathology 
Deletion of band 1p32 
Disease: Acute lymphoblastic 
leukemia/lymphoblastic lymphoma 
(ALL) 
Epidemiology 
The deletion is found in 9 cases ALL - 0.08% of all 
ALL cases with an abnormal karyotype: 3 cases with 
T-ALL (Schoch et al, 1996; Jarosova et al, 2016), 5 
cases with B-ALL (Kristofferson et al, 1985; Pui et 
al, 1990; Pui et al, 1992; Ivanov Ofverholm et al, 
2016) and 1 case without data on the cell phenotype 
(Prigogina et al, 1988).  
The patients with T-cell phenotype are males. The 
sex ratio of the cases with B-cell phenotype is 
M:F=1.5:1. The average age is 22.1 year (range 2-
74). 
Cytogenetics 
In six cases del(1)(q32) are with complex 
predominantly di- or hyperdiploid karyotypes.  
In two cases 1p32 deletion is accompanied with a 
second anomaly; one case with a T-cell phenotype 
has t(8;14)(q24;q11) and another with a B-cell 
phenotype del(12)(p12).  
In three cases the deletion is presented as additional 
deleted chromosome 1. 
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Disease: Follicular lymphoma (FL) 
Epidemiology 
The 1p32 deletion is described in 8 cases - 0.53% of 
all FL cases with an abnormal karyotype) (Yunis et 
al, 1984; Gaunt et al, 1986; Offit et al, 1989; Goyns 
et al, 1993; Wiodarska et al, 1994; Horsman et al, 
2001; Aamot et al, 2007).  
The sex ratio is M:F=1:1.7 The average age is 51.2 
year (range 43-62) (the age of 5 cases is reported). 
Cytogenetics 
The cases are presented predominantly with highly 
complex di- or hyperdiploid karyotypes. In 7 cases 
the 1p32 deletion is associated with 
t(14;18)(q32;q21).  
In four cases the anomaly is accompanied with 
structural aberration of chromosome 6. 
Disease: Diffuse large B-cell 
lymphoma (DBCL) 
Epidemiology 
Six cases are reported - 0.42% of all DBCL cases 
with an abnormal karyotype (Fukuhara et al, 1983; 
Ebrahim et al 1990; Weisenburger et al, 1996; 
Ichinohasama et al, 2000; Fan & Rizkalla, 2003; 
Kaneko et al, 2011).  
The sex ratio is M:F=2:1. The average age is 51.5 
year (range 36-65) (the age of 4 cases is reported). 
Cytogenetics 
The reported cases are predominantly with highly 
complex hyperdiploid or hypertetraploid karyotypes. 
In four cases the 1p32 deletion is associated with 
structural anomalies affecting 3q including the 
BCL6 locus 3q27.  
In three cases are found T-lineage anomalies - 14q11 
rearrangements in two cases and t(2;5)(p23;q35) in 
one case and in two the B-lineage anomalies -  14q32 
rearrangements. 
Disease: Multiple myeloma (MM) 
Epidemiology 
Seven cases are described - 0.37% of all MM cases 
with an abnormal karyotype (Lewis & MacKenzie, 
1984; Dewalt et al, 1985; Seong et al, 1998; 
Weinlander et al, 1998; Lioveras et al, 2004; Wu et 
al, 2007). The sex ratio is M:F=0.8:1. Age is reported 
in two cases - 67 and 73 years. 
Cytogenetics 
All cases are with complex karyotypes. Three have 
hyperdiploid, one hypertetraploid, one 
pseudodiploid, and two hypodiploid karyotypes. In 
two cases an additional 1p32 deletion is found.  
In four cases the anomaly is associated with other 
structural rearrangements of chromosome 1. 
Only in one case 14q32 rearrangement is described. 
Prognosis 
1p32 deletion is major negative prognostic factor for 
progression free survival and overall survival in the 
cases with MM (Hebraud B et al, 2014). 
Disease: Plasma cell leukemia (PCL) 
Cytogenetics 
Two cases (males; one 70 year old) are reported - 
1.32% of all PCL cases with an abnormal karyotype 
(Lewis & MacKenzie, 1984; Colovic et al, 2008). 
Both cases have a complex karyotype (one 
hypodiploid and another hyperdiplod with 14q32 
rearrangement). 
Disease: Hodgkin disease (HD) 
Cytogenetics 
Two cases are reported (males, 52 and 76 years old) 
- 3.8% of all HD cases with an abnormal karyotype 
(Schlegelberger et al, 1994; Busson-Le Coniat et al, 
1996).   
One is with an additional 1p32 deletion and another 
with a highly complex hyperdiploid karyotype 
carrying additional structural anomalies of 
chromosome 1.  
Both cases are with deletions of 6q. 
Disease: Anaplastic large cell 
lymphoma (ALCL) 
Epidemiology 
Three cases are reported (two males and one female; 
24, 40 and 52 years old) - 2.0% of all ALCL cases 
with an abnormal karyotype (Ebrahim et al, 1990; 
Falzetti et al, 1999; Colleoni et al, 2000).  Two of 
them are with a T-cell phenotype. 
Cytogenetics 
The three cases are with a complex karyotype.  
In one t(2;5)(p23;q35) is found and is associated 
with an additional 1p32 deletion and in another two 
copies of add(2)(p23).   
In all three cases the 1p32 deletion is accompanied 
with structural anomalies of chromosome 8, two of 
them with i(8)(q10). 
Disease: Adult T-cell 
lymphoma/leukemia (HTLV+) (ATCL) 
Cytogenetics 
Two cases with a complex karyotype are reported 
(males; 58 and 68 years old) - 0.75% of all ATCL 
cases with an abnormal karyotype (Sadamory et al, 
1986; Sadamory et al, 1991).  
In one the 1p32 deletion is presented as an additional 
anomaly. Both cases have structural aberrations 
involving chromosome 4. 
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SIL-TAL1 deletion 
Disease: T- Acute lymphoblastic 
leukemia/lymphoblastic lymphoma 
(T-ALL) 
Phenotype/cell stem origin 
Is restricted to TCR of the alpha, beta and TCR delta 
lineage with a deletion of one or both alleles of the 
TCR delta gene (Breit et al, 1993a).  TAL1 
expression appeared to reflect the cortical stage of 
thymocyte development (late double positive stage) 
(Ferrando AA et al, 1992). 
Etiology 
SIL-TAL1 deletion is mediated via illegitimate 
V(D)J recombination processes of T-cell receptor 
(TCR) gene (Aplan PD et al, 1990b). 
Epidemiology 
SIL-TAL1 deletion is observed in 3-26 % of cases 
with T-ALL (Aplan et al, 1990b; Brown et al, 1990). 
The anomaly is more frequent in males (D'Angio M 
et al, 2014). 
Clinics 
SIL-TAL1 deletion is associated with higher initial 
WBC count, T-lineage immunophenotype with CD2 
expression, predominant cortical T-phenotype, low 
incidence in adult patients and higher frequency of 
extramedullary relapse (Bash RO et al, 1993; Stock 
W et al, 1995; Mansur MB et al, 2009; D'Angio M 
et al, 2014). Increased risk from developing of tumor 
lysis syndrome and disseminated intravascular 
coagulation were also reported (Wang D et al, 2013). 
Cytogenetics 
SIL-TAL1 deletion represents a submicroscopic 
deletion of 90 Kb that affected all coding SIL exons. 
As a result of the deletion the first coding exons of 
TAL1 gene is juxtaposed to the promotor of SIL 
gene, causing its abnormal expression (Chen Q et al, 
1990b; Aplan PD et al, 1992b). The breakpoint in 
SIL gene remains constant while several breakpoints 
of the TAL1 gene have been identified, which leads 
to formation of two main (TAL1d1 and TAL1d2 in 
95% of the cases) and several rare types of SIL-
TAL1 deletions (Breit et al, 1993a). Almost half of 
the cases with SIL-TAL1 deletion have normal 
karyotypes. The rest of the cases are presented with 
hyperdiploid and more frequently with 
pseudodiploid  karyotypes associated with the 
structural anomalies del(6q) (7 cases), 
t(11;14)(p13;q11.2)/ t(11;14)(p15;q11.2) (3 cases) 
and t(8;14)(q24;q11.2) (1 case) (Wang Q et al, 2014; 
Cocce MC et al, 2015). 
Prognosis 
The data on the prognosis of the cases with SIL-
TAL1 deletion are controversial.  Mansur MB et al. 
(2009) reported negative impact on the patients, 
while no difference in survival and overall outcome 
were seen by D'Angio M et al. (2014). 
Genetics 
Using chromatin immunoprecipitation sequencing 
and chromosome conformation capture techniques, 
several scientific groups presented looping models 
for TAL1 expression in human and murine cell lines 
and described multiple interactions between TAL1 
and their cis-acting regulatory elements (1a and 1b 
TAL1 promotors, enhancers and CTCF bound 
elements) (Zhou Y et al, 2013; Lai F et al, 2013; 
Patel B et al, 2013). Zhou Y et al. (2013) find in 
TAL1 expressing cell lines that the regulatory hubs 
which control transcription bring the TAL/SIL 
common breakpoint regions (TALd) into close 
proximity. The authors suggest that the physical 
proximity between these regions in the committed 
lymphoid cells may predispose to SIL-TAL1 
deletion. However, the question remains: what is the 
reason that led to the rearrangement of the located in 
close proximity breakpoint regions? It should be 
noted that TAL1 gene is not expressed in the 
dividing double positive thymocytes, but SIL gene is 
expressed. In addition, the deletion primarily affects 
the SIL gene (all coding exons are deleted), so it can 
be assumed that the consequence of SIL-TAL1 
deletion is not only deregulation of the TAL1 gene, 
but also inactivation of the SIL gene. These 
considerations suggest that the generation of SIL-
TAL1 deletion is possibly due to a defective 
inactivation of the SIL gene which is intended to 
block the G2/M transition (through impairing the 
spindle assembly) and is a part of the  complex 
mechanisms that induced the apoptosis during 
thymocyte negative selection.  In this regard, future 
studies of looping patterns searching to discover the 
possible interactions leading to suppression of the 
SIL gene will elucidate the mechanisms of the 
formation of the SIL-TAL1 deletion as well as the 
role of the SIL gene in the regulation of the 
thymocyte apoptosis. 
Genes involved and 
proteins 
STIL 
Location 1p33 
STIL (or SIL: SCL interrupting locus) gene extended 
over 70 Kb and contained 18 exons.  
The gene encodes a large (150 kDa) cytosolic protein 
implicated in regulation of the mitotic spindle 
checkpoint. It is required for the procentriole 
assembly and the regulation of the centriole 
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duplication.  SIL mRNA expression is higher in 
rapidly proliferating cells and decreased rapidly 
during terminal differentiation. It is a positive 
regulator of the sonic hedgehog pathway and plays 
an important role in embryonic development. It is 
over expressed in multiple types of cancer and its 
expression correlates with the expression of mitotic 
checkpoint. 
TAL1 
Location 1p33 
TAL1 (T-cell acute leukemia 1) is a member of the 
class II helix-loop-helix (bHLH) family of 
transcription factors. The gene extended over 16 Kb 
and contained 6 exons. Have two isoforms: a long 
TAL1 (L) and short TAL1 (S). After 
heterodimerization with members of the class I 
bHLH proteins known as E proteins ( TCF3 (E2A), 
TCF12 (HEB), BHLHE22 (E2-2)), it binds E-box 
motif and forms complex with other transcription 
factors, including LMO, GATA1, RUNX1 and 
LDB1. TALl1 is expressed in hematopoietic stem 
cells, progenitor cells and erythro-megakaryocyte 
lineage. It is required for the specification of the 
haemangioblasts and the blood cell lineages and also 
plays a key role for the maturation of the 
megakaryocytes and erythroblasts (Porcher C et al, 
1996; Porcher C et al, 2017; Gering M et al, 1998; 
Schlaeger TM et al, 2005). TAL1 is transcriptionally 
silenced during normal lymphocyte development 
including at the stage of CD4+ CD8+ double-
positive thymocytes (the stage of maturation arrest 
of TAL1 positive T-ALL) (Tremblay M et al, 2010; 
Seita J et al, 2012). The transcriptional targets of the 
TAL1 in the normal hematopoietic cells are KIT, 
CDKN1A, DDIT4, KLF1, EPB42, GYPA, UBE2H 
and MEF2C (Lecuyer E et al, 2002; Lacombe J et al, 
2010; Benyoucef  A et al, 2015; Kassouf MT et al, 
2010; Xu Z et al, 2003). As part of the highly 
interconnected auto-regulated circuit, it controls the 
transcription factors LMO2, RUNX2, MYB and 
GATA2. Except through a SIL-TAL1 deletion, 
TAL1  deregulation occurs also as a result of the 
chromosome translocations t(1;14)(p32;q11) and 
t(1;7)(p32;q34) and through its ectopic expression 
(60% of the cases) (Ferrando AA et al, 2002). 
Recently another mechanism oduces a binding motif 
for MYB transcription factor (Mansour MR et al, 
2014). Deregulation of TAL1 inhibits E-proteins 
heterodimerization leading to block of T-cell 
differentiation. However, the oncogenic role of 
TAL1 in T-cell transformation is more complex and 
is linked to their influence on the function of the core 
regulatory circuitry (Sanda T et al, 2012) as well as 
on multiple downstream targets including ARID5B, 
NKX3-1, MYCN, CDKN2A, ALDH1A2 and 
MIR223 (Leong WZ et al, 2017; Kusy S et al, 2010; 
Astolfi A et al, 2014; Hansson A et al, 2003; Ono Y 
et al, 1998; Mansour MR et al, 2013). 
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